Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q2 FY19 results · Jul–Sep 2018
Lincoln Pharmaceuticals reported revenue from operations of ₹97.95 crore and net profit of ₹14.41 crore for Q2 FY19 (Jul–Sep 2018), on a standalone basis.
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 97.95 | — | — | 96.63 | +1.4% |
| Other income | 4.39 | — | — | 2.24 | +96.2% |
| Total income | 102.34 | — | — | 98.87 | +3.5% |
| Profit before tax | 17.96 | — | — | 21.95 | −18.2% |
| Net profit for the period | 14.41 | — | — | 15.60 | −7.7% |
| EPS, basic (₹) | 7.20 | — | — | 7.80 | −7.7% |
| Net margin (%) | 14.7 | — | 16.1 |
Standalone
- Filed with BSE
- 21 Nov 2018, 12:34 IST
- Board meeting
- 14 Nov 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE